The company states: “Mesoblast (MESO) Limited announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure, which reports that a single intramyocardial injection of the Company’s allogeneic cell therapy Revascor, or rexlemestrocel-L, results in improved survival in high-risk patients with ischemic heart failure and inflammation. Results from the randomized, controlled DREAM-HF trial in patients with chronic heart failure with reduced ejection fraction identified the control group at highest risk of cardiovascular death as being those with ischemic etiology and inflammation and showed that a single intramyocardial injection of Mesoblast’s mesenchymal precursor cell therapy resulted in a sustained reduction in cardiovascular mortality in these high-risk patients. This identifies the target HFrEF population that is responsive to REVASCOR therapy.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MESO:
- Largest borrow rate increases among liquid names
- Mesoblast Announces Director Change and Shareholdings
- MESO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mesoblast Issues 2 Million Warrants for Strategic Flexibility
- Mesoblast Poised for Breakthroughs in Cellular Medicine
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
